IRIS
CIANI, ORIANA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 11.912
NA - Nord America 9.177
AS - Asia 5.309
SA - Sud America 670
AF - Africa 178
OC - Oceania 35
Continente sconosciuto - Info sul continente non disponibili 21
Totale 27.302
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.768
IT - Italia 3.563
RU - Federazione Russa 2.988
FI - Finlandia 1.641
CN - Cina 1.593
SG - Singapore 1.406
IE - Irlanda 1.112
GB - Regno Unito 580
VN - Vietnam 548
BR - Brasile 523
UA - Ucraina 429
DE - Germania 425
HK - Hong Kong 418
FR - Francia 317
CA - Canada 303
BD - Bangladesh 285
SE - Svezia 247
TR - Turchia 226
IN - India 171
KR - Corea 156
NL - Olanda 153
ZA - Sudafrica 94
ID - Indonesia 77
MX - Messico 75
IL - Israele 72
PL - Polonia 68
BG - Bulgaria 58
CZ - Repubblica Ceca 55
KZ - Kazakistan 54
ES - Italia 46
IQ - Iraq 46
AR - Argentina 44
JP - Giappone 43
BE - Belgio 39
PK - Pakistan 37
AU - Australia 30
AT - Austria 28
EC - Ecuador 26
IR - Iran 25
RO - Romania 24
VE - Venezuela 23
MA - Marocco 21
PT - Portogallo 21
AE - Emirati Arabi Uniti 20
CH - Svizzera 18
LT - Lituania 18
EU - Europa 17
PH - Filippine 16
CL - Cile 15
CO - Colombia 15
TN - Tunisia 14
UZ - Uzbekistan 14
DK - Danimarca 13
AZ - Azerbaigian 12
EG - Egitto 12
MY - Malesia 12
SA - Arabia Saudita 11
KE - Kenya 10
HU - Ungheria 9
JO - Giordania 9
LV - Lettonia 9
NO - Norvegia 9
PE - Perù 9
GR - Grecia 8
TH - Thailandia 7
KG - Kirghizistan 6
OM - Oman 6
SN - Senegal 6
TT - Trinidad e Tobago 6
UY - Uruguay 6
DZ - Algeria 5
JM - Giamaica 5
LA - Repubblica Popolare Democratica del Laos 5
NG - Nigeria 5
PY - Paraguay 5
BO - Bolivia 4
BY - Bielorussia 4
ET - Etiopia 4
LU - Lussemburgo 4
MD - Moldavia 4
NP - Nepal 4
SI - Slovenia 4
SV - El Salvador 4
TW - Taiwan 4
AD - Andorra 3
AL - Albania 3
AM - Armenia 3
BH - Bahrain 3
CR - Costa Rica 3
GE - Georgia 3
HN - Honduras 3
LK - Sri Lanka 3
NZ - Nuova Zelanda 3
PA - Panama 3
SK - Slovacchia (Repubblica Slovacca) 3
BA - Bosnia-Erzegovina 2
CI - Costa d'Avorio 2
DO - Repubblica Dominicana 2
EE - Estonia 2
LB - Libano 2
Totale 27.269
Salva come PNG Salva come JPEG
Città #
Helsinki 1.533
Ashburn 1.370
Dublin 1.108
San Jose 1.096
Milan 744
Singapore 677
Chandler 673
Moscow 611
Hefei 553
Dallas 476
Hong Kong 410
Council Bluffs 345
Beijing 344
Jacksonville 335
New York 291
Rome 272
Ann Arbor 258
Southend 215
Los Angeles 211
Toronto 206
The Dalles 175
Edison 166
Redmond 149
Seoul 149
Dearborn 146
Ho Chi Minh City 142
Lauterbourg 137
Houston 131
Dong Ket 130
Wilmington 116
Hanoi 105
Boston 101
Modena 98
Lawrence 97
Boardman 92
Naples 85
Buffalo 84
Johannesburg 84
Munich 80
Izmir 71
Frankfurt am Main 68
Jakarta 68
Tel Aviv 66
São Paulo 65
Bologna 56
Orem 52
Santa Clara 52
Almaty 50
Redwood City 50
Seattle 50
Mountain View 48
Palombara Sabina 47
Warsaw 47
Lappeenranta 46
Chennai 44
Florence 40
Woodbridge 40
Tokyo 38
Turin 38
Genoa 37
Fairfield 36
Montreal 36
Bari 34
Mexico City 33
San Francisco 32
Atlanta 31
Brussels 31
Poplar 31
London 30
Nuremberg 30
Brooklyn 29
Denver 29
Stockholm 29
Chicago 28
Fremont 27
Washington 27
Catania 26
Amsterdam 24
Ottawa 24
Da Nang 21
Belo Horizonte 20
Brno 20
Guangzhou 20
Ankara 18
Assago 18
Verona 18
Brescia 16
Bucharest 16
Düsseldorf 16
Kunming 16
Mumbai 16
Nanjing 16
Palermo 16
Rio de Janeiro 16
Falkenstein 15
Vienna 15
West Jordan 15
Phoenix 14
Tashkent 14
Trieste 14
Totale 15.985
Salva come PNG Salva come JPEG
Nome #
EQ-5D-5L population norms for Italy 546
Esiti di salute e performance del Servizio Sanitario Nazionale 474
Prezzi di riferimento per dispositivi medici: criticità, vantaggi e approcci 446
La funzione di HTA nelle aziende sanitarie italiane: un potenziale ancora inutilizzato? 434
Dinamiche economiche e performance del settore dei dispositivi medici in Italia 390
I dispositivi medici in Italia: un settore, tanti mercati 347
PDTA per la chirurgia bariatrica: l'esperienza di 6 centri italiani 327
De innovatione: the concept of innovation for medical technologies and its implications for healthcare policy-making 316
Gli esiti di salute del Servizio Sanitario Nazionale 315
Exercise-based cardiac rehabilitation for chronic heart failure: the EXTRAMATCH II individual participant data meta-analysis 312
An EQ-5D-5L value set for Italy using videoconferencing interviews and feasibility of a new mode of administration 296
A network meta-analysis of everolimus plus exemestane versus chemotherapy in the first- and second-line treatment of estrogen receptor-positive metastatic breast cancer 288
Programma nazionale HTA per dispositivi medici: quali sfide per l’implementazione? 278
Establishing a national HTA program for medical devices in Italy: overhauling a fragmented system to ensure value and equal access to new medical technologies 274
La dimensione del settore dei dispositivi medici 273
An economic perspective on urinary tract infection: the "costs of resignation" 271
An electronic patient-reported outcome mobile app for data collection in type a hemophilia: design and usability study 256
Gli esiti di salute del Servizio Sanitario Nazionale 253
Myth #5: health care is rightly left to the private sector, for the sake of efficiency 252
A scoping review of core outcome sets and their 'mapping' onto real-world data using prostate cancer as a case study 247
Surrogate endpoints: a key concept in clinical epidemiology 246
Endpoint surrogati e politiche sanitarie: l’importanza di metodi di validazione adeguati 246
Current and Future Trends in the HTA of Medical Devices 245
Real-world data for the evaluation of transarterial radioembolization versus sorafenib in hepatocellular carcinoma: a cost-effectiveness analysis 245
A bias-adjusted evidence synthesis of RCT and observational data: the case of total hip replacement 241
Integrating HTA principles into procurement of medical devices: the Italian national HTA programme for medical devices 234
Hospital-based HTA: quale valore per la valutazione delle tecnologie nelle Aziende Sanitarie italiane? 225
Broadening the concept of value: a scoping review on the option value of medical technologies 224
A repeated cross-sectional analysis on the economic impact of SARS-CoV-2 pandemic at the hospital level in Italy 223
I processi di valutazione dei dispositivi medici e delle tecnologie sanitarie 221
Distinguishing features in the assessment of mHealth apps 221
Trans-arterial radioembolization in intermediate-advanced hepatocellular carcinoma: systematic review and meta-analyses 219
A randomized, open-label, multicenter study of the efficacy and safety of intravesical hyaluronic acid and chondroitin sulfate versus dimethyl sulfoxide in women with bladder pain syndrome/interstitial cystitis 219
Mapping payment and pricing schemes for health innovation: protocol of a scoping literature review 214
Surrogate endpoints in trials-a call for better reporting 212
Coverage with evidence development for medical devices in Europe: can practice meet theory? 210
A more evidence based approach to the use of surrogate end points in policy making 207
Value-based healthcare: il nuovo approccio di AIFA alla determinazione multidimensionale del valore 207
The Lung Cancer App (LuCApp) study protocol: a randomised controlled trial to evaluate a mobile supportive care app for patients with metastatic lung cancer 206
Measuring value in health care: a comparative analysis of value-based frameworks 203
Cost–effectiveness analysis of treatments involving radioembolization in intermediate-stage hepatocellular carcinoma 202
La gestione dell'innovazione tecnologica in sanità: analisi e confronto di alcune politiche regionali in Italia 201
Do existing real-world data sources generate suitable evidence for the HTA of medical devices in Europe? Mapping and critical appraisal 199
Coverage with evidence development schemes for medical devices in Europe: characteristics and challenges 199
European diabetes research and its funding, 2002–2013 198
Esiti di salute e performance del Servizio Sanitario Nazionale 197
Esiti di salute e performance del Servizio Sanitario Nazionale 197
Valutare l’impatto dell’HTA come strumento di governo dell’innovazione tecnologica: modelli teorici e studi empirici 197
Harnessing digital health technologies during and after the COVID-19 pandemic: context matters 195
Surrogate endpoints in health technology assessment: an international review of methodological guidelines 192
Breast-cancer specific comprehensive archive of Patient-Reported Outcome Measures (PROMs) for clinical research and clinical practice in oncology: results from the PRO4All project 191
Esiti di salute e performance del Servizio Sanitario Nazionale 190
Trans-arterial radioembolization for intermediate-advanced hepatocellular carcinoma: a budget impact analysis 190
Assessment of nonfatal myocardial infarction as a surrogate for all-cause and cardiovascular mortality in treatment or prevention of coronary artery disease: a meta-analysis of randomized clinical trials 190
Corona-regionalism? Differences in regional responses to COVID-19 in Italy 190
Strumenti a supporto del processo decisionale condiviso in oncologia 187
Combining tumour response and progression free survival as surrogate endpoints for overall survival in advanced colorectal cancer 187
Cost-effectiveness analysis of oral nutritional supplements with nutritional counselling in head and neck cancer patients undergoing radiotherapy. 185
Development features and study characteristics of mobile health apps in the management of chronic conditions: a systematic review of randomised trials 185
Implementing shared decision-making interventions in breast cancer clinical practice: a scoping review 179
An accelerated access pathway for innovative high-risk medical devices under the new European Union Medical Devices and health technology assessment regulations? Analysis and recommendations 177
Non-communicable diseases: mapping research funding organisations, funding mechanisms and research practices in Italy and Germany 177
Comparing drug and non-drug technologies in comparative effectiveness research 176
Design and features of pricing and payment schemes for health technologies: a scoping review and a proposal for a flexible need-driven classification 175
The Coronavirus pandemic and inequality in Italy 175
How are health technology assessment bodies responding to the assessment challenges posed by cell and gene therapy? 174
Core outcome set in surgical oncology: why, what and how to measure 173
The impact of surgical experience in VATS lobectomy on conversion and patient quality of life: results from a comprehensive national video-assisted thoracic surgical database 172
Valorizzare gli esiti riferiti dal paziente : opportunità e sfide 171
Mud-bath therapy in addition to usual care in bilateral knee osteoarthritis: economic evaluation alongside a randomized controlled trial 169
A call for better reporting of trials using surrogate primary endpoints 167
Associations between surrogate markers and clinical outcomes for nononcologic chronic disease treatments 167
Esiti di salute e performance del Servizio Sanitario Nazionale 167
Diffusion and use of Health Technology Assessment in policy making: what lessons for decentralised healthcare systems? 166
Introduction to economic evaluation and health technology assessment 165
Patient-reported outcome measures in core outcome sets targeted overlapping domains but through different instruments 165
Assessing the long-term prognostic ability of the 70 gene expression signature MammaPrint in an Italian single-center prospective cohort study of early-stage intermediate-risk breast cancer patients 163
A framework for the definition and interpretation of the use of surrogate endpoints in interventional trials 163
Time to review the role of surrogate end points in health policy: state of the art and the way forward 163
Il settore dei dispositivi medici in Italia. L’impatto delle politiche pubbliche sulle performance delle imprese 159
The development of an Archive of Patient-Reported Outcome Measures (PROMs) in Oncology: The Italian PRO4All Project 153
Validation of surrogate endpoints in advanced solid tumors: systematic review of statistical methods, results, and implications for policy makers 153
Exercise training for chronic heart failure (ExTraMATCH II): why all data are not equal 153
A Strategic Roadmap to Support Communication on and Acceptance of Surrogate Endpoints: The REnal Surrogacy accEpTance in Chronic Kidney Disease (RESET CKD) Collaboration 152
Validation of exercise capacity as a surrogate endpoint in exercise-based rehabilitation for heart failure: a meta-analysis of randomized controlled trials 152
Machine learning-assisted health economics and policy reviews: a comparative assessment 150
The evaluation of medical devices: are we getting closer to solve the puzzle? A review of recent trends 150
The impacts of diabetes research from 31 European Countries in 2002 to 2013 150
Recommendations for developing a lifecycle, multidimensional assessment framework for mobile medical apps 150
Surrogate endpoints in randomised trials of physiotherapy interventions: the SPIRIT and CONSORT extension checklists for better reporting 148
The role of patient-reported outcomes in reimbursement decisions and drug innovation in Italy 148
Direct healthcare costs of non-metastatic castration-resistant prostate cancer in Italy 146
Determinants of demand for total hip and and knee arthroplasty: a systematic literature review 146
Comparison of treatment effect sizes from pivotal and postapproval trials of novel therapeutics approved by the FDA based on surrogate markers of disease: a meta-epidemiological study 146
Complete cytogenetic response and major molecular response as surrogate outcomes for overall survival in first-line treatment of chronic myelogenous leukemia: a case study for technology appraisal on the basis of surrogate outcomes evidence 145
Intravesical administration of combined hyaluronic acid (HA) and chondroitin sulfate (CS) for the treatment of female recurrent urinary tract infections: a European multicentre nested case-control study 143
Health technology assessment methods guidelines for medical devices: how can we address the gaps? the international federation of medical and biological engineering perspective 142
Response to COVID-19: was Italy (un)prepared? 141
Value attribution for combination treatments: two potential solutions for an insoluble problem 140
The rise of rules: will the new regulation of medical devices make us safer? 140
Totale 21.246
Salva come PNG Salva come JPEG
Categoria #
all - tutte 110.076
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 110.076
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.500 107 220 50 68 140 66 58 233 72 145 143 198
2022/20233.178 202 173 86 266 203 223 83 162 1.398 121 161 100
2023/20242.436 109 142 149 59 258 287 193 324 98 180 303 334
2024/20253.372 108 71 228 172 179 195 276 245 961 384 341 212
2025/202613.021 758 986 365 850 1.023 463 1.387 1.224 3.492 1.542 586 345
2026/2027407 407 0 0 0 0 0 0 0 0 0 0 0
Totale 27.793